Fas Ligand DNA Enhances a Vaccination Effect by Coadministered DNA Encoding a Tumor Antigen through Augmenting Production of Antibody against the Tumor Antigen

Figure 3

Representative data on frequency of β-gal-specific CD8⁺ T cells in inguinal lymph nodes. BALB/c mice were pretreated with cardiotoxin and then uninjected (naive) or injected with pcDNA3 + pCAGGS, pcDNA3 + pCAGGS/FasL, pcDNA3/β-gal + pCAGGS, or pcDNA3/β-gal + pCAGGS/FasL (50 μg DNA for each). (a) Representative cell surface staining profiles of the lymph nodes 7 days after DNA immunization. The number indicates a percentage of each fraction. (b) Percentages of CD8⁺/β-gal-positive T cells in respective mice on days 7, 14, and 21 after DNA immunization. (c) Percentages of CD8⁺ T cells in respective mice on days 7, 14, and 21 after DNA immunization.

(a)

(b)

(c)